Literature DB >> 32095785

Regulation and New Treatment Strategies in Breast Cancer.

Rosa-Maria Ferraiuolo1, Kay-Uwe Wagner1.   

Abstract

Breast cancer classifications are based on the presence or absence of estrogen receptor and progesterone receptor along with the overexpression or amplification of the Her2 receptor. Although the overall 5-year survival rate of breast cancer patients has increased due to the use of targeted therapies, a subset of patients can acquire resistance over time or are unresponsive when presented in the clinic. Novel therapies focusing on molecular pathways and cell cycle regulation currently being used in the clinic may lead to increased response in this subset of patients.

Entities:  

Keywords:  Breast cancer; CDK; CKI; cell cycle; therapeutics

Year:  2019        PMID: 32095785      PMCID: PMC7039658     

Source DB:  PubMed          Journal:  J Life Sci (Westlake Village)        ISSN: 2688-1020


  109 in total

Review 1.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

Review 2.  Effects of membrane trafficking on signaling by receptor tyrosine kinases.

Authors:  Marta Miaczynska
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

4.  Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.

Authors:  Kongming Wu; Chenguang Wang; Mark D'Amico; Richard J Lee; Chris Albanese; Richard G Pestell; Sridhar Mani
Journal:  Mol Cancer Ther       Date:  2002-07       Impact factor: 6.261

5.  Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.

Authors:  Dongpo Cai; Vaughan M Latham; Xinxin Zhang; Geoffrey I Shapiro
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

Review 6.  Cisplatin: mode of cytotoxic action and molecular basis of resistance.

Authors:  Zahid H Siddik
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

7.  p107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15.

Authors:  L L Parker; S Atherton-Fessler; H Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

Review 8.  The anthracyclines: will we ever find a better doxorubicin?

Authors:  R B Weiss
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929

9.  Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.

Authors:  M J Kennedy; D K Armstrong; A M Huelskamp; K Ohly; B V Clarke; O M Colvin; L B Grochow; T L Chen; N E Davidson
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.

Authors:  F R Kohn; N E Sladek
Journal:  Biochem Pharmacol       Date:  1985-10-01       Impact factor: 5.858

View more
  1 in total

1.  Upregulated Long Non-Coding RNA LL22NC03-N64E9.1 Promotes the Proliferation and Migration of Human Breast Cancer Cells by Silencing Kruppel-Like Factor 2 Expression.

Authors:  Weibin Lian; Xiaohua Jiang; Liangqiang Li; Qinglan Wang; Chengye Hong; Peidong Yang; Debo Chen
Journal:  Cancer Manag Res       Date:  2020-10-29       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.